What do a patent dispute over a CRISPR/Cas system, a rejected whistleblower case involving lab tests and a vaccine injury claim parading as multidistrict tort litigation have in common? All three were denied cert in the U.S. Supreme Court’s latest orders list.

Montclair State University and the University of Maryland have discovered new dual 3’,5’-cyclic-AMP and -GMP phosphodiesterase 11A4 (PDE11A4) inhibitors potentially useful for the treatment of cognitive disorders.

The University of Toronto has patented new histone deacetylase 6 (HDAC6) inhibitors designed for use in the treatment of cancer, inflammation, neurodegeneration, infections, renal, neuromuscular, respiratory disorders and cardiometabolic syndrome.

Biofront Ltd. has designed new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety as HPK1 degradation inducers. They are described as potentially useful for the treatment of cancer.

Tyligand Bioscience Ltd. has reported new dual-drug antibody-drug conjugates comprising monoclonal antibodies covalently linked to stimulator of interferon genes protein (STING; TMEM173) agonist and a cytotoxic drug.

Nimbus Salacia Inc. has disclosed new serine/threonine-protein kinase SIK2 (QIK) inhibitors potentially useful for the treatment of autoimmune disease, cancer, diabetes, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis and skin hyperpigmentation, among others.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has discovered new glucocorticoid receptor (GR) agonists potentially useful for the treatment of rheumatoid arthritis, idiopathic arthritis, systemic lupus erythematosus, asthma, ulcerative colitis, neuromyelitis optica and autoimmune liver disease.

Nanjing Sanhome Pharmaceutical Co. Ltd. has synthesized new Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer.

Work at Ventus Therapeutics US Inc. has led to the identification of new caspase-4 allosteric and/or caspase-5 inhibitors reported to be useful for the treatment of sepsis, stroke, myocardial infarction, acute respiratory distress syndrome, inflammatory bowel disease, hidradenitis suppurativa, diabetic nephropathy and diabetic retinopathy, among others.

Rapt Therapeutics Inc. has patented new fused ring imidazole compounds acting as TNF-α modulators and thus reported to be useful for the treatment of cancer, pain, metabolic and autoimmune disease, inflammation, neurological, cardiovascular and eyes disorders.